D,l-sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing

Circulation Journal

Volumn 73, Issue 10, 2009, Pages 1820-1828

  Sakamoto, Tamotsu ^a   Fujiki, Akira ^a   Nakatani, Yosuke ^a   Sakabe, Masao ^a   Mizumaki, Koichi ^a   Hashimoto, Norio ^b   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Atrial fibrillation; D,l sotalol; Electrical remodeling; L type Ca 2+ channel; LV dysfunction

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL L TYPE ALPHA1C; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV4.3; SOTALOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REFRACTORY PERIOD; NONHUMAN; PROTEIN EXPRESSION;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; CALCIUM CHANNELS, L-TYPE; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; DOGS; DOWN-REGULATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FIBROSIS; HEART ATRIA; RNA, MESSENGER; SHAL POTASSIUM CHANNELS; SOTALOL; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 70349859864     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0321     Document Type: Article

References (31)

1. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
2. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525. (Pubitemid 27432738)
3. Gaspo R, Bosch RF, Abboud EB, Nattel S. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81: 1045-1052. (Pubitemid 27514955)
4. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999; 84: 776-784. (Pubitemid 29181484)
5. Van Gelder IC, Brundel BJ, Henning RH, Tuinenburg AE, Tieleman RG, Deelman L, et al. Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 552-560. (Pubitemid 29215336)
6. Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, et al. Downregulation of L-type calcium channel and sarcoplasmic reticular Ca2+-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban. J Am Coll Cardiol 1999; 33: 1231-1237.
7. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003; 107: 1440-1446. (Pubitemid 36350745)
8. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
9. Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J 1999; 137: 388-409.
10. Workman AJ, Kane KA, Russell JA, Norrie J, Rankin AC. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: Evidence of pharmacological remodeling. Cardiovasc Res 2003; 58: 518-525. (Pubitemid 36694437)
11. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570-1573.
12. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: Electrophysiological remodeling. Circulation 1996; 94: 2953-2960. (Pubitemid 26411765)
13. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation 1997; 96: 1675-1685. (Pubitemid 27375369)
14. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100: 87-95. (Pubitemid 29297945)
15. Shinagawa K, Li D, Leung TK, Nattel S. Consequences of atrial tachycardia induced remodeling depend on the preexisting atrial substrate. Circulation 2002; 105: 251-257. (Pubitemid 34084327)
16. Shinagawa K, Mitamura H, Ogawa S, Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002; 54: 438-446. (Pubitemid 34327922)
17. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475. (Pubitemid 36959891)
18. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: Importance of use-dependent effects on refractoriness. Circulation 1993; 88: 1030-1044. (Pubitemid 23264020)
19. Wijffels MCEF, Dorland R, Allessie MA. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: A comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol. J Cardiovasc Electrophysiol 1999; 10: 178-193. (Pubitemid 29115241)
20. Wijffels MCEF, Dorland R, Mast F, Allessie MA. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000; 102: 260-267. (Pubitemid 30451786)
21. Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005; 67: 69-76. (Pubitemid 40803460)
22. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920.
23. AFFIRM First Antiarrhythmic Drug Substudy Investigators: Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42: 20-29.
24. Osaka T, Yamazaki M, Yokoyama E, Ito A, Kodama I. Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. J Cardiovasc Electrophysiol 2004; 15: 877-884. (Pubitemid 39180244)
25. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000; 101: 2631-2638. (Pubitemid 30350643)
26. Groh WJ, Gibson KJ, McAnulty JH, Maylie JG. Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol. Circulation 1995; 91: 262-264.
27. Nattel S, Feder-Elituv R, Matthews C, Nayebpour M, Talajic M. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. J Am Coll Cardiol 1989; 13: 1190-1194. (Pubitemid 19091309)
28. Nishida K, Fujiki A, Sakamoto T, Iwamoto J, Mizumaki K, Hashimoto N, et al. Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tachycardia. J Cardiovasc Electrophysiol 2007; 18: 765-772. (Pubitemid 46934525)
29. Ishizaka T, Takahara A, Iwasaki H, Mitsumori Y, Kise H, Nakamura Y, et al. Comparison of Electropharmacological Effects of bepridil and sotalol in halothane-anesthetized dogs. Circ J 2008; 72: 1003-1011. (Pubitemid 351879925)
30. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30: 791-798. (Pubitemid 27397663)
31. Miyazaki A, Ohuchi H, Kurosaki K, Kamakura S, Yagihara T, Yamada O. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 2008; 72: 1998-2003.